» Articles » PMID: 15377699

Frequency of Orthostatic Hypotension in a Community Based Cohort of Patients with Parkinson's Disease

Overview
Date 2004 Sep 21
PMID 15377699
Citations 40
Authors
Affiliations
Soon will be listed here.
Abstract

The frequency of orthostatic hypotension (OH) in cohorts of patients recruited through hospital Parkinson's disease (PD) clinics ranges from 16% to 58%. However, hospital based cohorts may be subject to ascertainment bias. The aim of this study was to determine the frequency of OH in a community based population of PD patients and to determine the demographic features of patients with and without OH. Forty two (47%) of patients met the criteria for OH. Subjects with OH were older than those without OH, but there was no difference in PD disease duration or severity, MMSE or depression rating between the groups.

Citing Articles

Investigating the Interplay between Cardiovascular and Neurodegenerative Disease.

Cousineau J, Dawe A, Alpaugh M Biology (Basel). 2024; 13(10).

PMID: 39452073 PMC: 11505144. DOI: 10.3390/biology13100764.


Diagnostic and therapeutic challenges in PD-associated non-motor symptoms: the roles of neurologists and consultant physicians.

Ip C, Kassubek J, Storch A, Tonges L, Wolz M, Jost W J Neural Transm (Vienna). 2024; 131(10):1263-1273.

PMID: 39370478 DOI: 10.1007/s00702-024-02838-3.


Ampreloxetine Versus Droxidopa in Neurogenic Orthostatic Hypotension: A Comparative Review.

Hoxhaj P, Shah S, Muyolema Arce V, Khan W, Sadeghzadegan A, Singh S Cureus. 2023; 15(5):e38907.

PMID: 37303338 PMC: 10257554. DOI: 10.7759/cureus.38907.


Cardiovascular Autonomic Dysfunction in Parkinson's Disease: Editorial Commentary.

Chakravarty K, Ray S Ann Indian Acad Neurol. 2022; 25(5):805-806.

PMID: 36560981 PMC: 9764908. DOI: 10.4103/aian.aian_709_22.


Targeting α-Synuclein in Parkinson's Disease by Induced Pluripotent Stem Cell Models.

Spathopoulou A, Edenhofer F, Fellner L Front Neurol. 2022; 12:786835.

PMID: 35145469 PMC: 8821105. DOI: 10.3389/fneur.2021.786835.